tiprankstipranks
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
PremiumPress ReleasesAnnovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
6d ago
Annovis Bio Issues Key Update on Corporate Progress
PremiumCompany Announcements
Annovis Bio Issues Key Update on Corporate Progress
9d ago
Annovis Bio rises 8.3%
PremiumThe Fly
Annovis Bio rises 8.3%
9d ago
Annovis Bio downgraded to Hold from Buy at Maxim
PremiumThe FlyAnnovis Bio downgraded to Hold from Buy at Maxim
15d ago
Annovis Bio price target lowered to $26 from $36 at Canaccord
PremiumThe Fly
Annovis Bio price target lowered to $26 from $36 at Canaccord
15d ago
Annovis Bio falls -69.5%
PremiumThe Fly
Annovis Bio falls -69.5%
16d ago
Annovis Bio Inc trading halted, news pending
PremiumThe FlyAnnovis Bio Inc trading halted, news pending
16d ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
19d ago
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
22d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100